About six months ago, management had what he called a “revelation” that the firm could work in this new realm because MNM discovered that about 30 percent of patients with triple-negative breast cancer had tumors with a unique genomic signature.
MNM Bioscience began as a bioinformatics company that curates data and then builds artificial intelligence-based algorithms, but it is now looking to branch out into oncology drug target discovery.
About six months ago, management had what he called a “revelation” that the firm could work in this new realm because MNM discovered that about 30 percent of patients with triple-negative breast cancer had tumors with a unique genomic signature.
With entire genomes at hand, scientists can pinpoint DNA fragments responsible for different cancers and predict patient responses to cancer treatments. However, the sheer volume of whole-genome data makes it difficult to encode the characteristics of genomic variants as features for machine learning algorithms.
